Improving STING agonist-based cancer therapy by inhibiting the autophagy-related protein VPS34.

IF 6.5 2区医学 Q1 IMMUNOLOGY

Oncoimmunology Pub Date : 2024-06-11 eCollection Date: 2024-01-01 DOI:10.1080/2162402X.2024.2364958

Elisabetta Bartolini, Kris Van Moer, Bassam Janji

引用次数: 0

Abstract

We have recently demonstrated that inhibiting VPS34 enhances T-cell-recruiting chemokines through the activation of the cGAS/STING pathway using the STING agonist ADU-S100. Combining VPS34 inhibitors with ADU-S100 increased cytokine release and improved tumor control in mouse models, suggesting a potential synergy between VPS34 inhibition and therapies based on STING agonists.

查看原文本刊更多论文

通过抑制自噬相关蛋白 VPS34 改进基于 STING 激动剂的癌症疗法。

我们最近利用 STING 激动剂 ADU-S100 证实，抑制 VPS34 可通过激活 cGAS/STING 通路增强 T 细胞募集趋化因子。在小鼠模型中，将 VPS34 抑制剂与 ADU-S100 结合使用可增加细胞因子的释放并改善肿瘤控制，这表明 VPS34 抑制与基于 STING 激动剂的疗法之间存在潜在的协同作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncoimmunology ONCOLOGYIMMUNOLOGY-IMMUNOLOGY

CiteScore

12.50

自引率

2.80%

发文量

276

审稿时长

24 weeks

期刊介绍： OncoImmunology is a dynamic, high-profile, open access journal that comprehensively covers tumor immunology and immunotherapy. As cancer immunotherapy advances, OncoImmunology is committed to publishing top-tier research encompassing all facets of basic and applied tumor immunology. The journal covers a wide range of topics, including: -Basic and translational studies in immunology of both solid and hematological malignancies -Inflammation, innate and acquired immune responses against cancer -Mechanisms of cancer immunoediting and immune evasion -Modern immunotherapies, including immunomodulators, immune checkpoint inhibitors, T-cell, NK-cell, and macrophage engagers, and CAR T cells -Immunological effects of conventional anticancer therapies.